Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Morphology guided spatial transcriptomics to study topography of Hodgkin reed sternberg cells interaction with tumor microenvironment and its impact in defining risk of progression in classical Hodgkin lymphoma.

Benedetta Donati, Tanja Lazic, Riccardo Valli, Rexhep Durmo, Attilio Gennaro, Cristian Ascione, Pierluigi Di Chiaro, Alessia Ruffini, Manuel Gotti, Luca Arcaini, Erica Travaglino, Marco Paulli, Francesco Merli, Alessia Ciarrocchi, Stefano Luminari

Blood (2025) 146 (Supplement 1): 5315.

https://doi.org/10.1182/blood-2025-5315

Published: 2025

Journal Articles

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 7636.

https://doi.org/10.1182/blood-2025-7636

Published: 2025

Journal Articles

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 3722.

https://doi.org/10.1182/blood-2025-3722

Published: 2025

Journal Articles

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Blood (2025) 146 (Supplement 1): 3721.

https://doi.org/10.1182/blood-2025-3721

Published: 2025

Journal Articles

Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update

Blood (2024) 144 (Supplement 1): 3046.

https://doi.org/10.1182/blood-2024-200323

Published: 2024

Journal Articles

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4442.

https://doi.org/10.1182/blood-2023-186800

Published: 2023

Journal Articles

Ibrutinib Alone or in Combination with R-CHOP Chemoimmunotherapy in Relapsed or Refractory Primary Central Nervous System Lymphoma (rrPCNSL): A «Real-Life» Study

Blood (2022) 140 (Supplement 1): 6678–6680.

https://doi.org/10.1182/blood-2022-170143

Published: 2022

Journal Articles

Molecular Characterization of Diffuse Large B-Cell Lymphoma Associated to Hepatitis C Virus Infection

Blood (2021) 138 (Supplement 1): 2402.

https://doi.org/10.1182/blood-2021-152636

Published: 2021

Journal Articles

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

Blood (2018) 132 (Supplement 1): 401.

https://doi.org/10.1182/blood-2018-99-110289

Published: 2018

Journal Articles

Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma

Armando Santoro, MD, Rita Mazza, MD, Alessandro Pulsoni, MD, Alessandro Re, MD, Maurizio Bonfichi, MD, Vittorio Ruggero Zilioli, Flavia Salvi, Antonella Anastasia, MD, Stefano Luminari, MD, Manuel Gotti, MD, Annalisa Peli, MD, Anna Marina Liberati, MD, Nicola Di Renzo, MD, Luca Castagna, MD, Laura Giordano, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 1628.

https://doi.org/10.1182/blood-2018-99-118931

Published: 2018

Journal Articles

ABC Subtype, TP53 Mutation and BCL2 Overexpression are Associated with a Worse Outcome in Untreated Poor-Risk Young Diffuse Large B-Cell Lymphoma: Results from the Frontline Phase III BIO-DLBCL04 Study of the Fondazione Italiana Linfomi

Blood (2017) 130 (Supplement 1): 4010.

https://doi.org/10.1182/blood.V130.Suppl_1.4010.4010

Published: 2017

Journal Articles

Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Blood (2016) 128 (22): 472.

https://doi.org/10.1182/blood.V128.22.472.472

Published: 2016

Journal Articles

Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program

Vittorio Stefoni, Federico Sottotetti, Manuel Gotti, Michele Spina, Stefano Volpetti, Simone Ferrero, Francesco Spina, MD, Francesco Pisani, Michele Merli, Carlo Visco, MD, Rossella Paolini, Vittorio Ruggero Zilioli, Luca Baldini, MD Prof, Nicola Di Renzo, Patrizia Tosi, Nicola Cascavilla, MD, Stefano Molica, MD, Lisa Argnani, Pier Luigi Zinzani, MD PhD

Blood (2016) 128 (22): 2985.

https://doi.org/10.1182/blood.V128.22.2985.2985

Published: 2016

Journal Articles

LNK mutations in familial myeloproliferative neoplasms

Elisa Rumi, Ashot S. Harutyunyan, Daniela Pietra, Jelena D. Milosevic Feenstra, Chiara Cavalloni, Elisa Roncoroni, Ilaria Casetti, Marta Bellini, Chiara Milanesi, Maria C. Renna, Manuel Gotti, Cesare Astori, Robert Kralovics, Mario Cazzola

Blood (2016) 128 (1): 144–145.

https://doi.org/10.1182/blood-2016-04-711150

Published: 2016

Journal Articles

The Prognostic Role of Cell of Origin Profile and Myc Expression Assessed By Immunohistochemistry in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of First-Line Randomized BIO-DLCL04 Trial of Fondazione Italiana Linfomi (FIL)

Annalisa Chiappella, Claudio Agostinelli, Maurizio Martelli, Simona Righi, Andrea Evangelista, Emanuele Angelucci, Monica Balzarotti, Angelo Michele Carella, Manuel Gotti, Domenico Novero, MD, Giuseppe Rossi, MD, Caterina Stelitano, Marco Ladetto, Gianluca Gaidano, Stefano A Pileri, Umberto Vitolo

Blood (2015) 126 (23): 5041.

https://doi.org/10.1182/blood.V126.23.5041.5041

Published: 2015

Journal Articles

Outcome of Transformed Marginal Zone Lymphomas Treated in the Rituximab Era

Chiara Rusconi, MD, Maria Luisa Guerrera, MD, Alessandra Tedeschi, MD, Michelle Zancanella, MD, Manuel Gotti, MD, Michele Nichelatti, Sara Rattotti, MD, Lara Crucitti, MD, Marco Frigeni, Erika Meli, MD, Paola Picardi, MD, Anna Maria Frustaci, MD, Roberta Sciarra, Vittorio Ruggero Zilioli, MD, Periana Minga, MD, Marco Paulli, Roberto Cairoli, MD, Luca Arcaini

Blood (2015) 126 (23): 5098.

https://doi.org/10.1182/blood.V126.23.5098.5098

Published: 2015

Journal Articles

Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Armando Santoro, MD, Rita Mazza, MD, Alessandro Pulsoni, MD, Alessandro Re, Maurizio Bonfichi, MD, Vittorio Ruggero Zilioli, MD, Flavia Salvi, MD, Antonella Anastasia, Stefano Luminari, MD, Manuel Gotti, MD, Annalisa Peli, Anna Marina Liberati, MD, Nicola Di Renzo, Luca Castagna, Laura Giordano, Carmelo Carlo-Stella, MD

Blood (2015) 126 (23): 581.

https://doi.org/10.1182/blood.V126.23.581.581

Published: 2015

Journal Articles

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma

Blood (2015) 126 (8): 950–956.

https://doi.org/10.1182/blood-2014-12-616474

Published: 2015

Includes: Supplemental data

Journal Articles

Do Leukemic Cells and Mesenchymal Stem Cells (MSCs) From AML Patients Share The Same Chromosomal Defect? A Cytogenetics, FISH and aCGH/Snpa Study

Paolo Bernasconi, Irene Dambruoso, Manuel Gotti, Marina Boni, Rita Zappatore, PhD, Celeste Calvello, BSc, Claudia del Fante, Gianluca Viarengo, MD, Marilla Cervio, Cesare Perotti, MD

Blood (2013) 122 (21): 2602.

https://doi.org/10.1182/blood.V122.21.2602.2602

Published: 2013

Journal Articles

Non-Hodgkin's Lymphomas Associated With Positive Hepatitis-C Virus Infection: A Prospective Multicentric Observational Study On Behalf Of The “Rete Ematologica Lombarda/Hematology Network Of Lombardia Region”

Sara Rattotti, Luca Arcaini, Virginia Valeria Ferretti, Andrea Rossi, Stefano Fogazzi, Antonino Greco, Luca Baldini, Monica Balzarotti, Pietro Pioltelli, Maurizio Bonfichi, Marzia Varettoni, Manuel Gotti, Lucia Farina, Andrés J.M. Ferreri, Daniele Laszlo, Enrica Morra, MD

Blood (2013) 122 (21): 3003.

https://doi.org/10.1182/blood.V122.21.3003.3003

Published: 2013

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Morphology guided spatial transcriptomics to study topography of Hodgkin reed sternberg cells interaction with tumor microenvironment and its impact in defining risk of progression in classical Hodgkin lymphoma.

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

Ibrutinib Alone or in Combination with R-CHOP Chemoimmunotherapy in Relapsed or Refractory Primary Central Nervous System Lymphoma (rrPCNSL): A «Real-Life» Study

Molecular Characterization of Diffuse Large B-Cell Lymphoma Associated to Hepatitis C Virus Infection

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma

ABC Subtype, TP53 Mutation and BCL2 Overexpression are Associated with a Worse Outcome in Untreated Poor-Risk Young Diffuse Large B-Cell Lymphoma: Results from the Frontline Phase III BIO-DLBCL04 Study of the Fondazione Italiana Linfomi

Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma Treated in Italy According to the Ibrutinib Named Patient Program

LNK mutations in familial myeloproliferative neoplasms

The Prognostic Role of Cell of Origin Profile and Myc Expression Assessed By Immunohistochemistry in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of First-Line Randomized BIO-DLCL04 Trial of Fondazione Italiana Linfomi (FIL)

Outcome of Transformed Marginal Zone Lymphomas Treated in the Rituximab Era

Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma

Do Leukemic Cells and Mesenchymal Stem Cells (MSCs) From AML Patients Share The Same Chromosomal Defect? A Cytogenetics, FISH and aCGH/Snpa Study

Non-Hodgkin's Lymphomas Associated With Positive Hepatitis-C Virus Infection: A Prospective Multicentric Observational Study On Behalf Of The “Rete Ematologica Lombarda/Hematology Network Of Lombardia Region”

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only